Merck & Co. Inc. (MRK) News

Merck & Co. Inc. (MRK): $110.85

0.76 (+0.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MRK News Items

MRK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MRK News Highlights

  • For MRK, its 30 day story count is now at 23.
  • Over the past 16 days, the trend for MRK's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • DOW, DRUG and IMGO are the most mentioned tickers in articles about MRK.

Latest MRK News From Around the Web

Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.

3 High-Yielding Stocks That Are Up 27%-Plus This Year

This year has been one in which many investors have been flocking to safe stocks, including ones that pay dividends. As a result, many normally safe stocks that generate only modest gains have been producing oversized returns for investors. Three stocks that have dwarfed the S&P 500 this year and that are up over 20% and also pay a high rate of dividends include Merck (NYSE: MRK), General Mills (NYSE: GIS), and Chevron (NYSE: CVX).

Yahoo | December 7, 2022

4 Defensive Stocks to Prepare Your Portfolio for a Recession

Amid the rising possibility of a recession, defensive stocks with solid prospects will cushion investors from market jitters while their robust fundamentals ensure higher returns. ADM, HSY, UNH and MRK are some such stocks.

Yahoo | December 7, 2022

Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 76%

If you want to know who really controls Merck & Co., Inc. ( NYSE:MRK ), then you'll have to look at the makeup of its...

Yahoo | December 7, 2022

Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?

GOSS stock is plunging over 70%.

Larry Ramer on InvestorPlace | December 6, 2022

Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients

Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday. The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, and plans to launch a Phase 3 trial enrolling only those patients by the end of this year, Mirati Chief Executive Officer David Meek told Reuters. The trial will compare the adagrasib combination with the current standard of care, which is chemotherapy plus Keytruda, also known as pembrolizumab.

Yahoo | December 5, 2022

The Zacks Analyst Blog Highlights Caterpillar, Merck, UnitedHealth Group and Walmart

Caterpillar, Merck, UnitedHealth Group and Walmart are included in this Analyst Blog.

Yahoo | December 5, 2022

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.73

Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 9th of January to...

Yahoo | December 3, 2022

Should Investors Consider These 3 Low-Beta Stocks?

During times of heightened volatility, adding low-beta stocks can help blend in an extra layer of portfolio defense.

Yahoo | December 2, 2022

In Burkina Faso, a Personal Mission To Make a Difference in One Community

Merck & Co., Inc.

Yahoo | December 2, 2022

Top 4 Blue-Chip Stocks to Enhance Your Portfolio in December

We have narrowed our search to four Dow stocks. These are: CAT, WMT, MRK, UNH.

Yahoo | December 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6662 seconds.